[Assessment of the efficacy and safety of alemtuzumab in patients with highly active relapsing-remitting multiple sclerosis in Russian population].

Stella Sivertseva A M Prilenskaya E V Popova E L Turova L I Volkova I V Smagina E Yu Elchaninova A I Afanas'eva Zoya A Goncharova E A Markova N M Yarosh K Z Bakhtiyarova M A Sherman Alexey Boyko

Published in: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2023)

All patients experienced IRs of varying degrees of severity. A decrease in the score on the EDSS disability scale was noted. MT did not affect the occurrence or severity of IRs.

Keyphrases

multiple sclerosis
white matter
end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
disease activity
rheumatoid arthritis
patient reported outcomes